-transparent.png){kind=logo}
Bufuralol is a beta-adrenoceptor blocking drug whose oxidative metabolism is under the same genetic control as debrisoquine and sparteine. The pharmacokinetics of bufuralol were studied in 10 healthy subjects (7 extensive and 3 poor metabolizers of debrisoquine) after oral and intravenous administration. In extensive metabolizers the systemic availability of bufuralol was 43%. Poor metabolizers were characterized by a considerable increase in systemic availability due to a corresponding decrease in hepatic first-pass metabolism. After oral administration of bufuralol non-linear kinetics may occur.
Related Publications
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
January 1986,
European journal of clinical pharmacology,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
January 1990,
Pharmacology & therapeutics,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
January 1990,
Pharmacology & therapeutics,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
June 1984,
European journal of clinical investigation,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
April 1993,
British journal of clinical pharmacology,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
October 1991,
British journal of clinical pharmacology,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
April 1980,
Clinical pharmacology and therapeutics,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
November 1995,
Drug metabolism and disposition: the biological fate of chemicals,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
January 1989,
European journal of clinical pharmacology,
P Dayer, and
L Balant, and
A Kupfer, and
R Striberni, and
T Leemann
October 1990,
Pharmacology & toxicology,
